Further examination of various administration protocols of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia in myelosuppressed mice

Hiromichi Akahori, Masako Ozai, Masumi Ida, Kazunori Shibuya, Takashi Kato, Hiroshi Miyazaki

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Thrombopoietin (TPO) is the recently isolated lineage-dominant hematopoietic factor that plays a pivotal role in the regulation of megakaryocytopoiesis and thrombopoiesis. In vivo studies have shown that daily multiple injections of pegylated human megakaryocyte growth and development factor (PEG-rHuMGDF), a truncated molecule related to human TPO, modified with polyethylene glycol, greatly improve thrombocytopenia and in most cases anemia and neutropenia in myelosuppressed animal models. In this study, we further examined various administration protocols of PEG-rHuMGDF on thrombocytopenia in mice treated with a combination of irradiation and carboplatin. After the myelosuppressive treatment on Day 0, mice received the same amount of PEG-rHuMGDF beginning on Day 1 by a single, 3 times (on alternate days), or 7 day daily administration. A single injection of PEG- rHuMGDF significantly reduced the severity and duration of thrombocytopenia and anemia with a concomitant accelerated recovery of megakaryocytic and erythroid progenitors in the bone marrow, similar to the 2 other administration protocols. As the start of a single injection of PEG-rHuMGDF was delayed, its therapeutic effects were attenuated. These results indicate that an administration of PEG-rHuMGDF at an earlier time after the myelosuppressive treatment is necessary to improve thrombocytopenia and anemia.

Original languageEnglish
Pages (from-to)58-64
Number of pages7
JournalTherapeutic Apheresis
Volume2
Issue number1
Publication statusPublished - 1998 Feb
Externally publishedYes

Fingerprint

Thrombocytopenia
Thrombopoietin
Thrombopoiesis
Anemia
Injections
Carboplatin
Therapeutic Uses
Neutropenia
polyethylene glycol-recombinant human megakaryocyte growth and development factor
Animal Models
Bone Marrow
Therapeutics

Keywords

  • Anemia
  • Megakaryocyte
  • Megakaryocyte growth and development factor
  • Platelet
  • Thrombocytopenia
  • Thrombopoietin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Further examination of various administration protocols of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia in myelosuppressed mice. / Akahori, Hiromichi; Ozai, Masako; Ida, Masumi; Shibuya, Kazunori; Kato, Takashi; Miyazaki, Hiroshi.

In: Therapeutic Apheresis, Vol. 2, No. 1, 02.1998, p. 58-64.

Research output: Contribution to journalArticle

@article{249efa19f2804268914c255e95e12b8e,
title = "Further examination of various administration protocols of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia in myelosuppressed mice",
abstract = "Thrombopoietin (TPO) is the recently isolated lineage-dominant hematopoietic factor that plays a pivotal role in the regulation of megakaryocytopoiesis and thrombopoiesis. In vivo studies have shown that daily multiple injections of pegylated human megakaryocyte growth and development factor (PEG-rHuMGDF), a truncated molecule related to human TPO, modified with polyethylene glycol, greatly improve thrombocytopenia and in most cases anemia and neutropenia in myelosuppressed animal models. In this study, we further examined various administration protocols of PEG-rHuMGDF on thrombocytopenia in mice treated with a combination of irradiation and carboplatin. After the myelosuppressive treatment on Day 0, mice received the same amount of PEG-rHuMGDF beginning on Day 1 by a single, 3 times (on alternate days), or 7 day daily administration. A single injection of PEG- rHuMGDF significantly reduced the severity and duration of thrombocytopenia and anemia with a concomitant accelerated recovery of megakaryocytic and erythroid progenitors in the bone marrow, similar to the 2 other administration protocols. As the start of a single injection of PEG-rHuMGDF was delayed, its therapeutic effects were attenuated. These results indicate that an administration of PEG-rHuMGDF at an earlier time after the myelosuppressive treatment is necessary to improve thrombocytopenia and anemia.",
keywords = "Anemia, Megakaryocyte, Megakaryocyte growth and development factor, Platelet, Thrombocytopenia, Thrombopoietin",
author = "Hiromichi Akahori and Masako Ozai and Masumi Ida and Kazunori Shibuya and Takashi Kato and Hiroshi Miyazaki",
year = "1998",
month = "2",
language = "English",
volume = "2",
pages = "58--64",
journal = "Therapeutic Apheresis and Dialysis",
issn = "1744-9979",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Further examination of various administration protocols of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia in myelosuppressed mice

AU - Akahori, Hiromichi

AU - Ozai, Masako

AU - Ida, Masumi

AU - Shibuya, Kazunori

AU - Kato, Takashi

AU - Miyazaki, Hiroshi

PY - 1998/2

Y1 - 1998/2

N2 - Thrombopoietin (TPO) is the recently isolated lineage-dominant hematopoietic factor that plays a pivotal role in the regulation of megakaryocytopoiesis and thrombopoiesis. In vivo studies have shown that daily multiple injections of pegylated human megakaryocyte growth and development factor (PEG-rHuMGDF), a truncated molecule related to human TPO, modified with polyethylene glycol, greatly improve thrombocytopenia and in most cases anemia and neutropenia in myelosuppressed animal models. In this study, we further examined various administration protocols of PEG-rHuMGDF on thrombocytopenia in mice treated with a combination of irradiation and carboplatin. After the myelosuppressive treatment on Day 0, mice received the same amount of PEG-rHuMGDF beginning on Day 1 by a single, 3 times (on alternate days), or 7 day daily administration. A single injection of PEG- rHuMGDF significantly reduced the severity and duration of thrombocytopenia and anemia with a concomitant accelerated recovery of megakaryocytic and erythroid progenitors in the bone marrow, similar to the 2 other administration protocols. As the start of a single injection of PEG-rHuMGDF was delayed, its therapeutic effects were attenuated. These results indicate that an administration of PEG-rHuMGDF at an earlier time after the myelosuppressive treatment is necessary to improve thrombocytopenia and anemia.

AB - Thrombopoietin (TPO) is the recently isolated lineage-dominant hematopoietic factor that plays a pivotal role in the regulation of megakaryocytopoiesis and thrombopoiesis. In vivo studies have shown that daily multiple injections of pegylated human megakaryocyte growth and development factor (PEG-rHuMGDF), a truncated molecule related to human TPO, modified with polyethylene glycol, greatly improve thrombocytopenia and in most cases anemia and neutropenia in myelosuppressed animal models. In this study, we further examined various administration protocols of PEG-rHuMGDF on thrombocytopenia in mice treated with a combination of irradiation and carboplatin. After the myelosuppressive treatment on Day 0, mice received the same amount of PEG-rHuMGDF beginning on Day 1 by a single, 3 times (on alternate days), or 7 day daily administration. A single injection of PEG- rHuMGDF significantly reduced the severity and duration of thrombocytopenia and anemia with a concomitant accelerated recovery of megakaryocytic and erythroid progenitors in the bone marrow, similar to the 2 other administration protocols. As the start of a single injection of PEG-rHuMGDF was delayed, its therapeutic effects were attenuated. These results indicate that an administration of PEG-rHuMGDF at an earlier time after the myelosuppressive treatment is necessary to improve thrombocytopenia and anemia.

KW - Anemia

KW - Megakaryocyte

KW - Megakaryocyte growth and development factor

KW - Platelet

KW - Thrombocytopenia

KW - Thrombopoietin

UR - http://www.scopus.com/inward/record.url?scp=0031832946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031832946&partnerID=8YFLogxK

M3 - Article

C2 - 10227790

AN - SCOPUS:0031832946

VL - 2

SP - 58

EP - 64

JO - Therapeutic Apheresis and Dialysis

JF - Therapeutic Apheresis and Dialysis

SN - 1744-9979

IS - 1

ER -